PACB

PACB

Pacific Biosciences of California Inc. Common Stock

$1.160+0.000 (0.000%)

Цена в режиме реального времени

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$1.160

Максимум

$1.160

Минимум

$1.160

Объем

8.25M

Фундаментальные показатели компании

Статистические данные торговли

Связанные новости

PR Newswire

Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date

Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (Nasdaq: PACB), a leading...

Просмотреть больше
Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date
GlobeNewswire

PacBio to Present at Upcoming Investor Conferences

MENLO PARK, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the

Просмотреть больше
PacBio to Present at Upcoming Investor Conferences
GlobeNewswire

PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized

Просмотреть больше
PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene
Analyst Upgrades

Piper Sandler Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.25

Piper Sandler analyst David Westenberg maintains Pacific Biosciences with a Neutral and lowers the price target from $2 to $1.25.

Просмотреть больше
Piper Sandler Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.25
Analyst Upgrades

Stephens & Co. Reiterates Overweight on Pacific Biosciences, Maintains $1.8 Price Target

Stephens & Co. analyst Mason Carrico reiterates Pacific Biosciences with a Overweight and maintains $1.8 price target.

Просмотреть больше
Stephens & Co. Reiterates Overweight on Pacific Biosciences, Maintains $1.8 Price Target

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.